TaiwanJ Pharmaceuticals Valuation
Is 6549 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6549 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6549's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6549?
Other financial metrics that can be useful for relative valuation.
What is 6549's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$991.61m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 41.1x |
Enterprise Value/EBITDA | -176.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6549's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7x | ||
4170 Vectorite Biomedical | 12x | n/a | NT$671.9m |
7595 Pharmigene | 7.4x | n/a | NT$979.0m |
6814 Lukas Biomedical | 4.7x | n/a | NT$1.1b |
7561 Bioray Biotech | 3.7x | n/a | NT$719.0m |
6549 TaiwanJ Pharmaceuticals | 43.6x | n/a | NT$991.6m |
Price-To-Sales vs Peers: 6549 is expensive based on its Price-To-Sales Ratio (43.6x) compared to the peer average (7x).
Price to Earnings Ratio vs Industry
How does 6549's PE Ratio compare vs other companies in the TW Biotechs Industry?
Price-To-Sales vs Industry: 6549 is expensive based on its Price-To-Sales Ratio (43.6x) compared to the TW Biotechs industry average (22x).
Price to Sales Ratio vs Fair Ratio
What is 6549's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 43.6x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6549's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.